Maria Zowczak-Drabarczyk Miłosława, Murawa Dawid, Kaczmarek Leszek, Połom Karol, Litwiniuk Maria
Department of Clinical Biochemistry and Laboratory Medicine, Poznan University of Medical Sciences, Poznan, Poland.
1 Department of Surgical Oncology and General Surgery, Greater Poland Cancer Center in Poznań, Poland.
Contemp Oncol (Pozn). 2013;17(6):499-503. doi: 10.5114/wo.2013.38782. Epub 2013 Nov 25.
The aim of this pilot study was to evaluate the plasma total antioxidant capacity (TAS) in breast cancer patients in relation to ERβ expression.
The study group consisted of newly diagnosed consecutive female breast cancer patients (n = 41) and controls (n = 28) randomly selected from women with benign breast disease. TAS was determined with the ABTS reagent. Immunostaining for ERβ was performed using polyclonal antibodies. ERα, PgR and HER-2 were measured routinely (immunostaining for ERα and PgR with monoclonal antibodies and EnVision detection system; immunohistochemical method/FISH for HER-2 expression).
The plasma TAS was significantly decreased in the breast cancer patients in comparison to the controls independently of hormonal and lymph node status. The TAS level was not significantly different between breast cancer subgroups either in relation to the ERβ expression (ERβ+ vs. ERβ-) or considering the steroid receptor status (ERα+, ERβ+, Pg+ vs. ERα+, ERβ-, Pg+) even in the selected lymph node negative subgroup. Similarly, HER-2 expression did not significantly affect the TAS concentration. A tendency towards higher TAS level in all ERβ negative breast cancer subgroups was observed.
The results might confirm enhanced consumption of plasma antioxidants in breast cancer patients. The determination of ERβ isoforms along with parameters of redox status might enable better understanding of their mutual influence.
本初步研究旨在评估乳腺癌患者血浆总抗氧化能力（TAS）与雌激素受体β（ERβ）表达的关系。
研究组由新确诊的连续女性乳腺癌患者（n = 41）和从患有乳腺良性疾病的女性中随机选取的对照组（n = 28）组成。使用ABTS试剂测定TAS。使用多克隆抗体对ERβ进行免疫染色。常规检测ERα、孕激素受体（PgR）和人表皮生长因子受体2（HER-2）（使用单克隆抗体和EnVision检测系统对ERα和PgR进行免疫染色；采用免疫组织化学方法/荧光原位杂交法检测HER-2表达）。
与对照组相比，乳腺癌患者血浆TAS显著降低，且与激素和淋巴结状态无关。无论在ERβ表达方面（ERβ阳性与ERβ阴性）还是考虑类固醇受体状态（ERα阳性、ERβ阳性、Pg阳性与ERα阳性、ERβ阴性、Pg阳性），即使在选定的淋巴结阴性亚组中，乳腺癌亚组之间的TAS水平也无显著差异。同样，HER-2表达对TAS浓度也无显著影响。在所有ERβ阴性乳腺癌亚组中均观察到TAS水平有升高趋势。
结果可能证实乳腺癌患者血浆抗氧化剂消耗增加。测定ERβ亚型以及氧化还原状态参数可能有助于更好地理解它们之间的相互影响。
